Alkermes
diversified company with proven drug development and commercialization capabilities significant diverse revenues driving topline and positioned for growth pipeline of novel development candidates designed to target significant unmet needs proprietary commercial products that target large markets in addiction and psychiatry additional potential revenue streams as new products launch and grow licensed product oncology alfa phase advanced solid tumors preclinical advanced solid tumors enabling neurodegenerative and disorders agonist preclinical narcolepsy focus on profitability under review june focus on driving cost efficiencies and operating leverage while investing in the long term growth of high potential commercial and development stage products lye ors pend we a | Alkermes
Company
Deck Type
Deck date
March 2021
Slide
4 of 144
Similar slides by Alkermes
Investor Day
March 2021
Related slides by other companies
Results
March 2024
IPO
April 2022
Investor Presentation
July 2023
Investor Day
November 2021
Other recent decks by Alkermes
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io